Lyon, France, July 3, 2024–(BUSINESS WIRE)–During its annual “BIG UP” event, FrenchTech Saint-Etienne Lyon awarded the BIG Startup of the Year trophy to a startup that embodies the innovation and wealth of the region.
Founded in 2015, the non-profit organization French Tech Saint-Etienne Lyon promotes the creation, growth and internationalization of innovative companies in Lyon and Saint-Etienne.
Designated one of 17 French Technology Capitals by the French Government until 2026, it is aligned with the Ministry of Economy’s La Mission French Tech roadmap, integrating the Lyon-Saint-Étienne region into a network of more than 100 French technology communities across five continents.
The French Tech Capital and Community will act as an entry point for French startups to enter the global French tech ecosystem.
On June 17th, Brenus Pharma was selected as the BIG Start-up of the Year at a board meeting of French Tech Saint-Etienne Lyon, which brought together founders and CEOs of local startups, incubators, clusters, large corporations and other innovation stakeholders.
“Winning this award makes Brenus Pharma stand out among the 12 finalists, meeting the criteria of innovation and positive impact on our region. We are proud that Brenus Pharma has been recognized as a promising player in our network, perfectly reflecting the values of La Mission French Tech.Lucy Texier, director general of the French Polytechnique Institute Saint-Etienne-Lyon, said:
About French Tech Saint-Etienne Lyon:
French Tech Saint-Etienne Lyon consolidates and activates the local ecosystem with actors who support innovation. It contributes to the environmental and social transition for a sustainable and inclusive innovation and entrepreneurship region. The Association has more than 539 members, including 475 start-ups and 64 public and private partners.
About Brennus Pharma:
Brenus Pharma is a French biotechnology company developing a pioneering discovery platform, Stimulated-Tumor-Cell (STC), leading the way to a new generation of therapeutic cancer vaccines.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240703702575/en/
contact address
Marion Blanc
inquiry